Compare Moderna, Inc. (MRNA) vs SoFi Technologies Inc (SOFI) Price & Performance

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

SoFi Technologies (SOFI) trades at $17.64, up 2.08% today, amid a bearish technical signal but strong recent earnings beats. The stock is near its consensus price target low of $17.00, with revenue growth accelerating to $3.61 billion in 2025 and a net income margin of 13.32%. Cash flow trends show heavy reliance on financing activities, while assets have grown to $36.25 billion as of 2024. Recent news highlights upcoming Q2 2026 earnings on July 29, with management guiding for 30% top-line growth.

The outlook for SOFI hinges on sustained revenue expansion and profitability improvements, but risks include negative operating cash flows and competitive pressures. Analyst sentiment is mixed with a 33.33% buy rating, suggesting cautious optimism if execution meets guidance. The stock presents a potential opportunity if Q2 earnings beat expectations, yet volatility remains high given its fintech exposure and macroeconomic sensitivity.